US Consumer Health Industry In 2023: Mandatory Listing Has Supplement Sector’s Attention
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.
You may also be interested in...
Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive
Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.
Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act
Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.
Congress Boosts FDA Food Safety Budget Nearly $700M, Orders Reports On Formula Supply
Appropriators are “concerned by the fragility of the infant formula supply chain and the detrimental health impacts that can arise from shortage of these regulated products.” Their report published with FY2023 omnibus appropriations also asks for list of Russian firms with pending NDAs, including OTCs.